Literature DB >> 29078549

Recurrent laryngeal nerve lymph node dissection in minimally invasive esophagectomy.

Miao Lin1, Yaxing Shen1, Hao Wang1, Mingxiang Feng1, Lijie Tan1.   

Abstract

Minimally invasive esophagectomy (MIE) has become increasingly important in the treatment for resectable esophageal cancer. However, it's still controversial about the effects of recurrent laryngeal nerve (RLN) lymph node dissection in MIE. Patient was placed in the lateral prone position. RLN lymph node dissection was performed in MIE. MIE can get comparable results of RLN lymph node dissection as open surgery. The number of dissected lymph nodes is 9.8±4.3 pieces and the time of lymphadenectomy is about 24 mins. RLN lymph node dissection is feasible and safe in MIE. The helpful surgical techniques include clear exposure of RLN, good collaboration with assistant, esophageal suspension, and so on.

Entities:  

Keywords:  Lymph node dissection; esophageal cancer; minimally invasive esophagectomy (MIE); recurrent laryngeal nerve (RLN)

Year:  2016        PMID: 29078549      PMCID: PMC5638433          DOI: 10.21037/jovs.2016.10.02

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  8 in total

1.  Outcomes after minimally invasive esophagectomy: review of over 1000 patients.

Authors:  James D Luketich; Arjun Pennathur; Omar Awais; Ryan M Levy; Samuel Keeley; Manisha Shende; Neil A Christie; Benny Weksler; Rodney J Landreneau; Ghulam Abbas; Matthew J Schuchert; Katie S Nason
Journal:  Ann Surg       Date:  2012-07       Impact factor: 12.969

Review 2.  Minimally invasive versus open esophagectomy for cancer: a systematic review and meta-analysis.

Authors:  S S A Y Biere; M A Cuesta; D L van der Peet
Journal:  Minerva Chir       Date:  2009-04       Impact factor: 1.000

3.  Learning curve to lymph node resection in minimally invasive esophagectomy for cancer.

Authors:  Ankit Dhamija; Joshua E Rosen; Anish Dhamija; Bonnie E Gould Rothberg; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa
Journal:  Innovations (Phila)       Date:  2014 Jul-Aug

4.  Lymph node dissection in esophageal carcinoma: Minimally invasive esophagectomy vs open surgery.

Authors:  Bo Ye; Chen-Xi Zhong; Yu Yang; Wen-Tao Fang; Teng Mao; Chun-Yu Ji; Zhi-Gang Li
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

Review 5.  Minimally invasive esophagectomy for cancer.

Authors:  Georges Decker; Willy Coosemans; Paul De Leyn; Herbert Decaluwé; Philippe Nafteux; Dirk Van Raemdonck; Toni Lerut
Journal:  Eur J Cardiothorac Surg       Date:  2008-10-25       Impact factor: 4.191

Review 6.  Current status of minimally invasive esophagectomy for patients with esophageal cancer.

Authors:  Hiroya Takeuchi; Hirofumi Kawakubo; Yuko Kitagawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-05-10

7.  Minimally invasive Ivor Lewis esophagectomy: description of a learning curve.

Authors:  Luis F Tapias; Christopher R Morse
Journal:  J Am Coll Surg       Date:  2014-02-21       Impact factor: 6.113

8.  Minimally invasive esophagectomy for esophageal cancer in the People's Republic of China: an overview.

Authors:  Chengchu Zhu; Ketao Jin
Journal:  Onco Targets Ther       Date:  2013-03-03       Impact factor: 4.147

  8 in total
  2 in total

Review 1.  Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition).

Authors:  Hui Li; Wentao Fang; Zhentao Yu; Yousheng Mao; Longqi Chen; Jie He; Tiehua Rong; Chun Chen; Haiquan Chen; Keneng Chen; Ming Du; Yongtao Han; Jian Hu; Jianhua Fu; Xiaobin Hou; Taiqian Gong; Yin Li; Junfeng Liu; Shuoyan Liu; Lijie Tan; Hui Tian; Qun Wang; Jiaqing Xiang; Meiqing Xu; Xin Ye; Bin You; Renquan Zhang; Yan Zhao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Comparative study of three types of lymphadenectomy along the left recurrent laryngeal nerve by minimally invasive esophagectomy.

Authors:  Shuangping Zhang; Peng Zhang; Shiping Guo; Jianhong Lian; Yun Chen; Ailan Chen; Yong Ma; Feng Li
Journal:  Thorac Cancer       Date:  2019-12-20       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.